Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study assessing tipifarnib in combination with a PI3Kα inhibitor in relapsed/refractory head and neck squamous cell carcinoma (HNSCC)

Next Previous
Trial Profile

A phase I/II study assessing tipifarnib in combination with a PI3Kα inhibitor in relapsed/refractory head and neck squamous cell carcinoma (HNSCC)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 12 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antineoplastics (Primary) ; Tipifarnib (Primary)
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Kura Oncology

Most Recent Events

  • 06 May 2021 According to a Kura Oncology media release, the company expects to initiate this trial in the second half of 2021.
  • 05 Nov 2020 According to a Kura Oncology media release, the company expects to initiate this study in mid-2021.
  • 29 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top